Tryptophan hydroxylase gene associated with paroxetine antidepressant activity

Alessandro Serretti, Raffaella Zanardi, Cristina Cusin, David Rossini, Cristina Lorenzi, Enrico Smeraldi

Research output: Contribution to journalArticle

Abstract

The possible association of the A218C tryptophan hydroxylase (TPH) gene variant with the antidepressant activity of paroxetine was investigated in a sample of 121 inpatients affected by a major depressive episode and treated with paroxetine 20-40 mg with either placebo or pindolol in a double blind design for 4 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject using a PCR-based technique. TPH*A/A and TPH*A/C variants were associated with a poorer response to paroxetine treatment when compared to TPH*C/C (P=0.005); this difference was not present in the pindolol augmented group. Other variables, such as sex, diagnosis, presence of psychotic features, severity of depressive symptomatology at baseline and paroxetine plasma level, were not associated with the outcome. TPH gene variants are therefore a possible modulator of paroxetine antidepressant activity.

Original languageEnglish
Pages (from-to)375-380
Number of pages6
JournalEuropean Neuropsychopharmacology
Volume11
Issue number5
DOIs
Publication statusPublished - 2001

Fingerprint

Tryptophan Hydroxylase
Paroxetine
Antidepressive Agents
Genes
Pindolol
Depression
Inpatients
Placebos
Polymerase Chain Reaction

Keywords

  • Antidepressant treatment
  • Mood disorders
  • Pharmacogenetics
  • Pindolol

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. / Serretti, Alessandro; Zanardi, Raffaella; Cusin, Cristina; Rossini, David; Lorenzi, Cristina; Smeraldi, Enrico.

In: European Neuropsychopharmacology, Vol. 11, No. 5, 2001, p. 375-380.

Research output: Contribution to journalArticle

Serretti, Alessandro ; Zanardi, Raffaella ; Cusin, Cristina ; Rossini, David ; Lorenzi, Cristina ; Smeraldi, Enrico. / Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. In: European Neuropsychopharmacology. 2001 ; Vol. 11, No. 5. pp. 375-380.
@article{121a69130a7d4397bac5a2877eedf3a2,
title = "Tryptophan hydroxylase gene associated with paroxetine antidepressant activity",
abstract = "The possible association of the A218C tryptophan hydroxylase (TPH) gene variant with the antidepressant activity of paroxetine was investigated in a sample of 121 inpatients affected by a major depressive episode and treated with paroxetine 20-40 mg with either placebo or pindolol in a double blind design for 4 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject using a PCR-based technique. TPH*A/A and TPH*A/C variants were associated with a poorer response to paroxetine treatment when compared to TPH*C/C (P=0.005); this difference was not present in the pindolol augmented group. Other variables, such as sex, diagnosis, presence of psychotic features, severity of depressive symptomatology at baseline and paroxetine plasma level, were not associated with the outcome. TPH gene variants are therefore a possible modulator of paroxetine antidepressant activity.",
keywords = "Antidepressant treatment, Mood disorders, Pharmacogenetics, Pindolol",
author = "Alessandro Serretti and Raffaella Zanardi and Cristina Cusin and David Rossini and Cristina Lorenzi and Enrico Smeraldi",
year = "2001",
doi = "10.1016/S0924-977X(01)00113-4",
language = "English",
volume = "11",
pages = "375--380",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier Science B.V.",
number = "5",

}

TY - JOUR

T1 - Tryptophan hydroxylase gene associated with paroxetine antidepressant activity

AU - Serretti, Alessandro

AU - Zanardi, Raffaella

AU - Cusin, Cristina

AU - Rossini, David

AU - Lorenzi, Cristina

AU - Smeraldi, Enrico

PY - 2001

Y1 - 2001

N2 - The possible association of the A218C tryptophan hydroxylase (TPH) gene variant with the antidepressant activity of paroxetine was investigated in a sample of 121 inpatients affected by a major depressive episode and treated with paroxetine 20-40 mg with either placebo or pindolol in a double blind design for 4 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject using a PCR-based technique. TPH*A/A and TPH*A/C variants were associated with a poorer response to paroxetine treatment when compared to TPH*C/C (P=0.005); this difference was not present in the pindolol augmented group. Other variables, such as sex, diagnosis, presence of psychotic features, severity of depressive symptomatology at baseline and paroxetine plasma level, were not associated with the outcome. TPH gene variants are therefore a possible modulator of paroxetine antidepressant activity.

AB - The possible association of the A218C tryptophan hydroxylase (TPH) gene variant with the antidepressant activity of paroxetine was investigated in a sample of 121 inpatients affected by a major depressive episode and treated with paroxetine 20-40 mg with either placebo or pindolol in a double blind design for 4 weeks. The severity of depressive symptoms was weekly assessed with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject using a PCR-based technique. TPH*A/A and TPH*A/C variants were associated with a poorer response to paroxetine treatment when compared to TPH*C/C (P=0.005); this difference was not present in the pindolol augmented group. Other variables, such as sex, diagnosis, presence of psychotic features, severity of depressive symptomatology at baseline and paroxetine plasma level, were not associated with the outcome. TPH gene variants are therefore a possible modulator of paroxetine antidepressant activity.

KW - Antidepressant treatment

KW - Mood disorders

KW - Pharmacogenetics

KW - Pindolol

UR - http://www.scopus.com/inward/record.url?scp=0034795789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034795789&partnerID=8YFLogxK

U2 - 10.1016/S0924-977X(01)00113-4

DO - 10.1016/S0924-977X(01)00113-4

M3 - Article

C2 - 11597824

AN - SCOPUS:0034795789

VL - 11

SP - 375

EP - 380

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 5

ER -